Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Xeris Biopharma Holdings, Inc.

We're a growth-oriented biopharmaceutical company improving patient lives by developing and commercializing advanced products across a range of therapies.

Oxford Finance LLC

Silicon Valley Bank

Armistice Capital

Deerfield

Asahi Kasei

Palmetto Partners

Bay City Capital

Wild Basin Investments

Merieux Developpement

Xeris Pharmaceuticals, Inc.

Wishing health, happiness, and prosperity to all celebrating the Lunar New Year! 
 
As many welcome the Year of the Dragon this week with hopes for a lucky year ahead, we at Xeris join in honoring the occasion. May it bring new beginnings filled with joy.
 
The values of compassion, care and community at the heart of this holiday inspire us daily in our mission. However you mark this festive time of renewal, we wish you the very best in the year to come.

#LunarNewYear #LunarNewYear2024 #YearOfTheDragon

Meet Emily, one of our Cushing’s Syndrome Patient Voices. In 2015, Emily’s diagnosis of Cushing’s came a year and a half after scans showed benign tumors on both of her adrenal glands. Her original endocrinologist did not look for Cushing’s, and it was not until she saw a new endocrinologist that her Cushing’s was diagnosed.

Although Emily does not look like other individuals who live with Cushing’s— for example, she is not overweight — an endocrinologist she saw for a routine follow-up check on her adrenal tumors noticed her cortisol was elevated and sent her to a Cushing’s specialist. That endocrinologist diagnosed Cushing’s.
 
Unfortunately, delay in diagnosis is far too common for many individuals living with a rare disease. Emily's advice to others living with Cushing's is to "remember that Cushing’s can look different in different people and remain compassionate — for yourself and others.”

We take pride in supporting #RareDiseaseMonth this February to raise awareness for those living with Cushing's and supporting those who treat it. We understand Cushing's is not a "one size fits all approach."

Connect with us through Xeris CareConnection™ to speak with a Patient Access Manager and learn more about Emily's story. Click here to sign up for support: https://lnkd.in/gPXvi5ZC
 
#Cushings #CushingDisease #CushingsSyndrome #RareDisease

We are so excited to be exhibiting at #PriMedSouth in Fort Lauderdale later this week! Visit Booth #322 to learn about the importance of having a safety net if you or a loved one is at risk for very low blood sugar. If you’re attending, let us know in the comments! 

Pri-Med

We are so honored to have our Gvoke HypoPen® influencer campaign chosen out of over 2,000 entries as both a Bronze Anthem Winner and a Community Voice Award Winner in the Social Media Content, Campaign or Channel category. Thank you to The Anthem Awards for recognizing the importance of equipping diabetes patients with a safety net to treat very low blood sugar. 
 
Check out our call to action here: https://lnkd.in/gPT9r2Qc and learn more about Gvoke HypoPen® (glucagon injection) at https://lnkd.in/gJX_xGiu.

#AnthemAwards #Diabetes #DiabetesAwareness #DiabetesCommunity #InfluencerMarketing #GvokeHypoPen

What is GVOKE? GVOKE is a prescription medicine used to treat very low blood sugar (severe hypoglycemia) in people with diabetes ages 2 years and above. It is not known if GVOKE is safe and effective in children under 2 years of age.

Do not use GVOKE if: you have a tumor in the gland on top of your kidneys (adrenal gland) called a pheochromocytoma, as it may cause a substantial increase in blood pressure; you have a tumor in your pancreas called an insulinoma, as it may cause low blood sugar; or if you are allergic to glucagon or any inactive ingredient in GVOKE.

GVOKE may cause other serious side effects, such as Serious skin rash -- in certain people with a tumor in their pancreas called a glucagonoma; Serious allergic reactions -- Call your doctor or get medical help right away if you have a serious allergic reaction including rash, difficulty breathing, low blood pressure.

See Important Safety Information: https://lnkd.in/gA79wrqT
 
See Full Prescribing Information: https://bit.ly/3baHqAO

Meet Jodi, one of our Cushing’s Syndrome Patient Voices. For Jodi, receiving a Cushing's diagnosis was validating because she had always believed her Cushing's-related symptoms were not her fault. A diagnosis proved to her that she was not to be blamed for her symptoms. 
 
As we shine a light on our patient voices throughout #RareDiseaseMonth, we encourage those living with a rare disease to always advocate for themselves just like Jodi has. We take pride in supporting Rare Disease Month this February to raise awareness for those living with Cushing’s and supporting those who treat it. Connect with us through Xeris CareConnection™ to speak with a Patient Access Manager and learn more about Jodi's story. Click here to sign up for support: https://lnkd.in/gPXvi5ZC
 
#Cushings #CushingDisease #CushingsSyndrome #RareDisease

Join clinical experts  David Lieb, MD, FACE, Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM, and Vin Tangpricha, MD, PhD, FACE as they discuss the 2022 AACE diabetes guideline updates and address the issue, “How Should Hypoglycemia Be Managed? Listen to the podcast today!

Are you looking for a rewarding new opportunity?

We're #hiring two Area Business Specialists to join the Xeris team!

To learn more and apply, visit https://bit.ly/499XFcU

#PharmaJobs #RareDiseases

Today, we join millions nationwide in remembrance of civil rights leader Dr. Martin Luther King Jr. His leadership and advocacy during the Civil Rights Movement led to monumental societal shifts that continue to pave the way for equality.
 
Dr. King organized peaceful demonstrations and delivered legendary speeches like "I Have a Dream" to galvanize support to end segregation and secure voting rights for all. His nonviolent resistance and call for people of all races, religions and backgrounds to unite in fellowship deeply impacted the conscience of America. 
 
Even with major milestones accomplished, Dr. King's dream remains unfinished. As we pause to honor his courage, we also recommit ourselves to enacting change. At Xeris, this means fostering a diverse, equitable and inclusive culture where all our employees feel welcomed, valued and empowered. We strive to incorporate Dr. King's values of compassion and human dignity into every aspect of our work.
 
We hope Dr. King's extraordinary message resonates with all our connections near and far.

#MLKDay #MartinLutherKingJr

If you're interested in working in the #diabetes space, we're hiring for Territory Business Representatives, Diabetes in Atlanta West, Omaha, Tulsa, and Central Georgia. Apply now! https://lnkd.in/gt82PnVe

#DiabetesCommunity #Hiring

Exciting news! Today we announced that Xeris has entered into an exclusive worldwide license agreement for Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab (known as TEPEZZA® in the United States) using our XeriJect® technology in Thyroid Eye Disease (TED) - a serious, progressive and potentially vision-threatening rare autoimmune disease. 

Read more: https://lnkd.in/gPcdGCVZ 

#ThyroidEyeDisease #PharmaNews #Pharmaceuticals

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	1.31M -	1.98M 50.27%	866K 56.17%	3.12M 259.93%	8.92M 186.30%	4.61M 48.39%	4.61M 0%	11.56M 151.09%
accumulated other comprehensive income loss	-268K -	-440K 64.18%	-52K 88.18%	6K 111.54%	-31K 616.67%	-23K 25.81%	-23K 0%	-25K 8.70%
cash and cash equivalents	32.27M -	42.05M 30.30%	45.72M 8.73%	37.60M 17.76%	67.27M 78.92%	121.97M 81.31%	121.97M 0%	67.45M 44.70%
cash and short term investments	32.27M -	42.05M 30.30%	112.63M 167.89%	133.79M 18.78%	102.43M 23.44%	121.97M 19.07%	121.97M 0%	72.45M 40.60%
common stock	1K -	1K 0%	2K 100%	6K 200%	13K 116.67%	14K 7.69%	14K 0%	14K 0%
deferred revenue	263K -	234K 11.03%	232K 0.85%				64.78M -
deferred revenue non current					6.88M -			34.76M -
deferrred tax liabilities non current					4.94M -	3.52M 28.81%	3.52M 0%	20.46M 481.69%
goodwill					22.86M -	120.61M 427.61%	120.61M 0%	22.86M 81.05%
goodwill and intangible assets					154.31M -	124.60M 19.25%	124.60M 0%	132.62M 6.44%
intangible assets					131.45M -	3.99M 96.96%	3.99M 0%	109.76M 2,649.60%
inventory				8.35M -	18.12M 116.90%	24.73M 36.52%	24.73M 0%	38.84M 57.02%
long term debt			31.89M -	87.02M 172.88%	88.07M 1.20%	196.48M 123.10%	196.48M 0%	190.93M 2.82%
long term investments				13.23M -				4.22M -
net debt	-32.27M -	-42.05M 30.30%	-13.83M 67.12%	49.42M 457.46%	20.80M 57.92%	76.09M 265.89%	76.09M 0%	161.74M 112.56%
net receivables	101K -	1.20M 1,087.13%	2.87M 139.28%	6.88M 139.63%	17.46M 153.91%	30.83M 76.62%	30.83M 0%	39.20M 27.14%
other assets
other current assets	804K -	809K 0.62%	2.40M 196.29%	3.20M 33.33%	4.59M 43.59%	9.29M 102.38%	9.29M 0%	5.78M 37.78%
other current liabilities	47K -	93K 97.87%	860K 824.73%	25.09M 2,817.44%	70.12M 179.46%	67.44M 3.82%	2.66M 96.06%	80.13M 2,914.79%
other liabilities
other non current assets	47K -	157K 234.04%	95K 39.49%	-13.00M 13,783.16%	829K 106.38%	4.73M 470.57%	4.73M 0%	315K 93.34%
other non current liabilities	62.94M -	97.97M 55.65%	2.56M 97.39%	10.16M 296.95%	30.20M 197.17%	25.72M 14.83%	25.72M 0%	6.23M 75.79%
othertotal stockholders equity	2.36M -	3.19M 35.11%	196.12M 6,040.29%	371.13M 89.24%	555.36M 49.64%	599.97M 8.03%	599.97M 0%	610.25M 1.71%
preferred stock
property plant equipment net	312K -	788K 152.56%	2.03M 158.12%	6.71M 229.74%	6.63M 1.19%	28.38M 328.17%	28.38M 0%	29.18M 2.82%
retained earnings	-34.03M -	-60.59M 78.03%	-120.67M 99.17%	-337.38M 179.60%	-460.11M 36.38%	-554.77M 20.57%	-554.77M 0%	-617.02M 11.22%
short term debt	902K -	2.56M 183.48%	8.21M 221.24%			1.58M -	1.58M 0%	3.50M 121.20%
short term investments			66.92M -	96.19M 43.75%	35.16M 63.45%	35.16M 0%		5.00M -
tax assets								18.20M -
tax payables
total assets	33.53M -	45.00M 34.19%	120.03M 166.74%	159.15M 32.59%	304.36M 91.24%	344.52M 13.20%	344.52M 0%	340.80M 1.08%
total current assets	33.17M -	44.05M 32.79%	117.90M 167.63%	152.21M 29.10%	142.60M 6.32%	186.82M 31.01%	186.82M 0%	156.26M 16.35%
total current liabilities	2.53M -	4.86M 92.32%	10.17M 109.30%	28.21M 177.30%	79.04M 180.21%	73.62M 6.86%	73.62M 0%	95.19M 29.30%
total debt			31.89M -	87.02M 172.88%	88.07M 1.20%	198.06M 124.89%	198.06M 0%	229.19M 15.72%
total investments			66.92M -	96.19M 43.75%	35.16M 63.45%	35.16M 0%		9.23M -
total liabilities	65.47M -	102.83M 57.07%	44.62M 56.61%	125.39M 181.00%	209.13M 66.78%	299.33M 43.13%	299.33M 0%	347.58M 16.12%
total liabilities and stockholders equity	33.53M -	45.00M 34.19%	120.03M 166.74%	159.15M 32.59%	304.36M 91.24%	344.52M 13.20%	344.52M 0%	340.80M 1.08%
total non current assets	359K -	945K 163.23%	2.13M 125.29%	6.94M 225.93%	161.76M 2,231.24%	157.70M 2.51%	157.70M 0%	184.53M 17.01%
total non current liabilities	62.94M -	97.97M 55.65%	34.45M 64.84%	97.18M 182.10%	130.09M 33.86%	225.71M 73.51%	225.71M 0%	252.39M 11.82%
total stockholders equity	-31.93M -	-57.83M 81.09%	75.41M 230.39%	33.76M 55.23%	95.23M 182.07%	45.19M 52.55%	45.19M 0%	-6.78M 115.01%

NASDAQ:XERS

Xeris Biopharma Holdings, Inc.

Last Close

1.86

03/05 20:00

Market Cap

343.93M

Beta: -

Volume Today

1.13M

Avg: 1.25M

PE Ratio

−4.97

PFCF: −4.75